Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
PLoS One
    January 2021
  1. SATPATHY S, Patra A, Hussain MD, Kazi M, et al
    A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells.
    PLoS One. 2021;16:e0240068.
    >> Share

  2. MOUSTAFA D, Elwahed MRA, Elsaid HH, Parvin JD, et al
    Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    PLoS One. 2021;16:e0235025.
    >> Share

  3. YUK JS, Lee B, Kim K, Kim MH, et al
    Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
    PLoS One. 2021;16:e0250723.
    >> Share

  4. ZHANG R, Yang X, Roque DM, Li C, et al
    A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
    PLoS One. 2021;16:e0240145.
    >> Share

  5. ZHANG L, Hu C, Huang Z, Li Z, et al
    In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: A comprehensive meta-analysis.
    PLoS One. 2021;16:e0250717.
    >> Share

  6. TOKUNAGA H, Iida K, Hozawa A, Ogishima S, et al
    Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    PLoS One. 2021;16:e0236907.
    >> Share

  7. PRAHM KP, Hogdall CK, Karlsen MA, Christensen IJ, et al
    MicroRNA characteristics in epithelial ovarian cancer.
    PLoS One. 2021;16:e0252401.
    >> Share

  8. WALSH CS, Kamrava M, Rogatko A, Kim S, et al
    Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
    PLoS One. 2021;16:e0252665.
    >> Share

  9. OYAMA Y, Shigeta S, Tokunaga H, Tsuji K, et al
    CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
    PLoS One. 2021;16:e0251079.
    >> Share

  10. GUI T, Yao C, Jia B, Shen K, et al
    Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.
    PLoS One. 2021;16:e0253136.
    >> Share

  11. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Wayne Novotny G, Hogdall CK, et al
    Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2021;16:e0255142.
    >> Share

  12. PARIS EA, Bahr JM, Bitterman P, Basu S, et al
    Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.
    PLoS One. 2021;16:e0255007.
    >> Share

  13. WANG H, Ye F, Zhou C, Cheng Q, et al
    High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
    PLoS One. 2021;16:e0245733.
    >> Share

  14. ALKHARUSI A, AlMuslahi A, AlBalushi N, AlAjmi R, et al
    Connections between prolactin and ovarian cancer.
    PLoS One. 2021;16:e0255701.
    >> Share

  15. CIRILLO PDR, Margiotti K, Fabiani M, Barros-Filho MC, et al
    Multi-analytical test based on serum miRNAs and proteins quantification for ovarian cancer early detection.
    PLoS One. 2021;16:e0255804.
    >> Share

  16. STEFANOU DT, Bamias A, Episkopou H, Kyrtopoulos SA, et al
    Correction: Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer.
    PLoS One. 2021;16:e0256051.
    >> Share

  17. MCCORKLE JR, Gorski JW, Liu J, Riggs MB, et al
    Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
    PLoS One. 2021;16:e0254205.
    >> Share

  18. JAREID M, Snapkov I, Holden M, Busund LR, et al
    The blood transcriptome prior to ovarian cancer diagnosis: A case-control study in the NOWAC postgenome cohort.
    PLoS One. 2021;16:e0256442.
    >> Share

  19. NAPOLI E, Bonsdorff TB, Jorstad IS, Bruland OS, et al
    Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use.
    PLoS One. 2021;16:e0248133.
    >> Share

    January 2020
  20. MIAO R, Badger TC, Groesch K, Diaz-Sylvester PL, et al
    Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
    PLoS One. 2020;15:e0227707.
    >> Share

  21. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    >> Share

  22. AYYAGARI VN, Wang X, Diaz-Sylvester PL, Groesch K, et al
    Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression-An in vitro study.
    PLoS One. 2020;15:e0228024.
    >> Share

  23. ARCHER S, Babb de Villiers C, Scheibl F, Carver T, et al
    Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study.
    PLoS One. 2020;15:e0229999.
    >> Share

  24. WEN H, Qian M, He J, Li M, et al
    Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-beta pathway.
    PLoS One. 2020;15:e0230230.
    >> Share

  25. WU W, Yu LH, Ma B, Xu MJ, et al
    Retraction: The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer.
    PLoS One. 2020;15:e0231890.
    >> Share

  26. LUBORSKY J, Barua A, Edassery S, Bahr JM, et al
    Inflammasome expression is higher in ovarian tumors than in normal ovary.
    PLoS One. 2020;15:e0227081.
    >> Share

  27. CHAMBERS LM, Esakov E, Braley C, AlHilli M, et al
    Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer.
    PLoS One. 2020;15:e0228511.
    >> Share

  28. KIM KK, Turner R, Khazan N, Kodza A, et al
    Role of trypsin and protease-activated receptor-2 in ovarian cancer.
    PLoS One. 2020;15:e0232253.
    >> Share

  29. ZENG Y, Chen M, Ganesh S, Hu S, et al
    Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer.
    PLoS One. 2020;15:e0232235.
    >> Share

  30. PRICE JC, Azizi E, Naiche LA, Parvani JG, et al
    Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    PLoS One. 2020;15:e0233962.
    >> Share

  31. OSTMEYER J, Lucas E, Christley S, Lea J, et al
    Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.
    PLoS One. 2020;15:e0229569.
    >> Share

  32. ANTON C, Kleine RT, Mayerhoff E, Diz MDPE, et al
    Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.
    PLoS One. 2020;15:e0229543.
    >> Share

  33. HAILU HE, Mondul AM, Rozek LS, Geleta T, et al
    Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia.
    PLoS One. 2020;15:e0230625.
    >> Share

  34. SOLDI R, Ghosh Halder T, Weston A, Thode T, et al
    The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    PLoS One. 2020;15:e0235705.
    >> Share

  35. PYEON SY, Han GH, Ki KD, Lee KB, et al
    Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer.
    PLoS One. 2020;15:e0236244.
    >> Share

  36. KELM NQ, Straughn AR, Kakar SS
    Withaferin A attenuates ovarian cancer-induced cardiac cachexia.
    PLoS One. 2020;15:e0236680.
    >> Share

  37. JOHNSON SC, Chakraborty S, Drosou A, Cunnea P, et al
    Inflammatory state of lymphatic vessels and miRNA profiles associated with relapse in ovarian cancer patients.
    PLoS One. 2020;15:e0230092.
    >> Share

  38. POLYMEROS K, Guttery DS, Hew R, Bishop R, et al
    Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
    PLoS One. 2020;15:e0233900.
    >> Share

  39. MITTEMPERGHER L, Piskorz AM, Bosma AJ, Michaut M, et al
    Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    PLoS One. 2020;15:e0235766.
    >> Share

  40. FADDA M, Chappuis PO, Katapodi MC, Pagani O, et al
    Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    PLoS One. 2020;15:e0240054.
    >> Share

  41. SAGLAM O, Tang Z, Tang G, Medeiros LJ, et al
    KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
    PLoS One. 2020;15:e0238477.
    >> Share

  42. SOPO M, Sallinen H, Hamalainen K, Kivela A, et al
    High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    PLoS One. 2020;15:e0241484.
    >> Share

  43. ESTERMANN M, Huang YL, Septiadi D, Ritz D, et al
    Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.
    PLoS One. 2020;15:e0241500.
    >> Share

  44. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Correction: Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2020;15:e0243944.
    >> Share

  45. LEANDERSSON P, Akesson A, Hedenfalk I, Malander S, et al
    A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    PLoS One. 2020;15:e0240418.
    >> Share

  46. WANG Y, Tao VL, Shin CY, Salamanca C, et al
    Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line.
    PLoS One. 2020;15:e0240412.
    >> Share

  47. PATRA B, Lateef MA, Brodeur MN, Fleury H, et al
    Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems.
    PLoS One. 2020;15:e0244549.
    >> Share

  48. BATES M, Spillane CD, Gallagher MF, McCann A, et al
    The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    PLoS One. 2020;15:e0243715.
    >> Share

    January 2019
  49. HEINZEL A, Marhold M, Mayer P, Schwarz M, et al
    Synthetic lethality guiding selection of drug combinations in ovarian cancer.
    PLoS One. 2019;14:e0210859.
    >> Share

  50. GONG W, Liu Y, Seidl C, Dreyer T, et al
    Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
    PLoS One. 2019;14:e0212968.
    >> Share

  51. NIU L, Li S, Liang H, Li H, et al
    Correction: The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.
    PLoS One. 2019;14:e0218032.
    >> Share

  52. FURRER D, Gregoire J, Turcotte S, Plante M, et al
    Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    PLoS One. 2019;14:e0218621.
    >> Share

  53. LINDGREN A, Anttila M, Rautiainen S, Arponen O, et al
    Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1alpha expression.
    PLoS One. 2019;14:e0221340.
    >> Share

  54. WICZLING P, Daghir-Wojtkowiak E, Kaliszan R, Markuszewski MJ, et al
    Bayesian multilevel model of micro RNA levels in ovarian-cancer and healthy subjects.
    PLoS One. 2019;14:e0221764.
    >> Share

  55. LIETZ AP, Weaver DT, Melamed A, Rauh-Hain JA, et al
    Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.
    PLoS One. 2019;14:e0222828.
    >> Share

  56. FRAGOSO-ONTIVEROS V, Velazquez-Aragon JA, Nunez-Martinez PM, de la Luz Mejia-Aguayo M, et al
    Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
    PLoS One. 2019;14:e0222709.
    >> Share

  57. GORZELITZ J, Costanzo ES, Spencer RJ, Rumble M, et al
    Longitudinal assessment of post-surgical physical activity in endometrial and ovarian cancer patients.
    PLoS One. 2019;14:e0223791.
    >> Share

  58. AMIT A, Sabo E, Movsas A, Efrat-Tamam Y, et al
    Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?
    PLoS One. 2019;14:e0211329.
    >> Share

  59. DURAN GE, Sikic BI
    The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
    PLoS One. 2019;14:e0210879.
    >> Share

  60. MRKVICOVA A, Chmelarova M, Peterova E, Havelek R, et al
    The effect of sodium butyrate and cisplatin on expression of EMT markers.
    PLoS One. 2019;14:e0210889.
    >> Share

  61. TORRES D, Hou X, Bale L, Heinzen EP, et al
    Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    PLoS One. 2019;14:e0224564.
    >> Share

  62. OLIVEIRA DNP, Carlsen AL, Heegaard NHH, Prahm KP, et al
    Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
    PLoS One. 2019;14:e0225249.
    >> Share

  63. WANG F, Chen X, Yuan D, Yi Y, et al
    Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells.
    PLoS One. 2019;14:e0225450.
    >> Share

  64. WAMBECKE A, Laurent-Issartel C, Leroy-Dudal J, Giffard F, et al
    Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.
    PLoS One. 2019;14:e0225860.
    >> Share

  65. ZHAO Y, Mehta M, Walton A, Talsania K, et al
    Robustness of RNA sequencing on older formalin-fixed paraffin-embedded tissue from high-grade ovarian serous adenocarcinomas.
    PLoS One. 2019;14:e0216050.
    >> Share

  66. CHE L, Yang X, Ge C, El-Amouri SS, et al
    Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.
    PLoS One. 2019;14:e0216553.
    >> Share

  67. MARTINEZ-MAS J, Bueno-Crespo A, Khazendar S, Remezal-Solano M, et al
    Evaluation of machine learning methods with Fourier Transform features for classifying ovarian tumors based on ultrasound images.
    PLoS One. 2019;14:e0219388.
    >> Share

  68. KIM B, Won D, Lee ST, Choi JR, et al
    Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
    PLoS One. 2019;14:e0217521.
    >> Share

  69. ZEH N, Schneider H, Mathias S, Raab N, et al
    Human CAP cells represent a novel source for functional, miRNA-loaded exosome production.
    PLoS One. 2019;14:e0221679.
    >> Share

  70. BISHOP MR, Huskey ALW, Hetzel J, Merner ND, et al
    A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.
    PLoS One. 2019;14:e0220929.
    >> Share

  71. ANDRADE DAP, da Silva VD, Matsushita GM, de Lima MA, et al
    Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
    PLoS One. 2019;14:e0220086.
    >> Share

    January 2018
  72. SHAHZAD MMK, Felder M, Ludwig K, Van Galder HR, et al
    Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src.
    PLoS One. 2018;13:e0189524.
    >> Share

  73. WANG KH, Wang YM, Chiu LH, Chen TC, et al
    Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    PLoS One. 2018;13:e0192047.
    >> Share

  74. LUO H, Xu X, Ye M, Sheng B, et al
    The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
    PLoS One. 2018;13:e0191972.
    >> Share

  75. ZHANG R, Pu W, Zhang S, Chen L, et al
    Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial.
    PLoS One. 2018;13:e0191756.
    >> Share

  76. SINGH G, Roy J, Rout P, Mallick B, et al
    Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers.
    PLoS One. 2018;13:e0190485.
    >> Share

  77. HOU S, Dai J
    Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer.
    PLoS One. 2018;13:e0192812.
    >> Share

  78. HYLER AR, Baudoin NC, Brown MS, Stremler MA, et al
    Fluid shear stress impacts ovarian cancer cell viability, subcellular organization, and promotes genomic instability.
    PLoS One. 2018;13:e0194170.
    >> Share

  79. NOEL-MACDONNELL JR, Usset J, Goode EL, Fridley BL, et al
    Assessment of data transformations for model-based clustering of RNA-Seq data.
    PLoS One. 2018;13:e0191758.
    >> Share

  80. CHUDECKA-GLAZ A, Cymbaluk-Ploska A, Wezowska M, Menkiszak J, et al
    Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
    PLoS One. 2018;13:e0194270.
    >> Share

  81. CHANG LC, Huang CF, Lai MS, Shen LJ, et al
    Prognostic factors in epithelial ovarian cancer: A population-based study.
    PLoS One. 2018;13:e0194993.
    >> Share

  82. NEYT M, Vlayen J, Devriese S, Camberlin C, et al
    First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
    PLoS One. 2018;13:e0195134.
    >> Share

  83. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeillinger R, et al
    Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2018;13:e0196142.
    >> Share

  84. ZHANG T, Xu J, Deng S, Zhou F, et al
    Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data.
    PLoS One. 2018;13:e0196351.
    >> Share

  85. AITHAL A, Junker WM, Kshirsagar P, Das S, et al
    Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    PLoS One. 2018;13:e0193907.
    >> Share

  86. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2018;13:e0197529.
    >> Share

  87. HECKL M, Schmoeckel E, Hertlein L, Rottmann M, et al
    The ARID1A, p53 and ss-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    PLoS One. 2018;13:e0192881.
    >> Share

  88. HE X, Yang K, Wang H, Chen X, et al
    Expression and clinical significance of survivin in ovarian cancer: A meta-analysis.
    PLoS One. 2018;13:e0194463.
    >> Share

  89. CAI Q, Fan Q, Buechlein A, Miller D, et al
    Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.
    PLoS One. 2018;13:e0197404.
    >> Share

  90. TEA MM, Tan YY, Staudigl C, Eibl B, et al
    Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
    PLoS One. 2018;13:e0200559.
    >> Share

  91. EARP M, Tyrer JP, Winham SJ, Lin HY, et al
    Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.
    PLoS One. 2018;13:e0197561.
    >> Share

  92. YEH CC, Su FH, Tzeng CR, Muo CH, et al
    Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study.
    PLoS One. 2018;13:e0194011.
    >> Share

  93. MITCHELL R, Buckingham L, Cobleigh M, Rotmensch J, et al
    Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
    PLoS One. 2018;13:e0195497.
    >> Share

  94. RHYASEN GW, Yao Y, Zhang J, Dulak A, et al
    BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
    PLoS One. 2018;13:e0200826.
    >> Share

  95. MONTAVON SARTORIUS C, Schoetzau A, Kettelhack H, Fink D, et al
    ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.
    PLoS One. 2018;13:e0195213.
    >> Share

  96. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    >> Share

  97. WANG KH, Wang YM, Chiu LH, Chen TC, et al
    Correction: Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    PLoS One. 2018;13:e0202610.
    >> Share

  98. LEE YJ, Lee IH, Kim YJ, Chung YS, et al
    Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    PLoS One. 2018;13:e0203366.
    >> Share

  99. ZHENG G, Yu H, Kanerva A, Forsti A, et al
    Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    PLoS One. 2018;13:e0205000.
    >> Share

  100. FUJISAWA M, Moh-Moh-Aung A, Zeng Z, Yoshimura T, et al
    Ovarian stromal cells as a source of cancer-associated fibroblasts in human epithelial ovarian cancer: A histopathological study.
    PLoS One. 2018;13:e0205494.
    >> Share

  101. ZHENG G, Yu H, Kanerva A, Forsti A, et al
    Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    PLoS One. 2018;13:e0206721.
    >> Share

  102. SHIH AJ, Menzin A, Whyte J, Lovecchio J, et al
    Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.
    PLoS One. 2018;13:e0206785.
    >> Share

  103. STARBUCK KD, Szender JB, Duncan WD, Morrell K, et al
    Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.
    PLoS One. 2018;13:e0206913.
    >> Share

  104. LIN ZP, Zhu YL, Lo YC, Moscarelli J, et al
    Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    PLoS One. 2018;13:e0207399.
    >> Share

  105. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    PLoS One. 2018;13:e0207319.
    >> Share

  106. SHIH AJ, Menzin A, Whyte J, Lovecchio J, et al
    Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.
    PLoS One. 2018;13:e0208778.
    >> Share

  107. YODSURANG V, Tang Y, Takahashi Y, Tanikawa C, et al
    Genome-wide association study (GWAS) of ovarian cancer in Japanese predicted regulatory variants in 22q13.1.
    PLoS One. 2018;13:e0209096.
    >> Share

  108. DEDOVA T, Grunow D, Kappert K, Flach D, et al
    The effect of blood sampling and preanalytical processing on human N-glycome.
    PLoS One. 2018;13:e0200507.
    >> Share

  109. EAVARONE DA, Al-Alem L, Lugovskoy A, Prendergast JM, et al
    Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.
    PLoS One. 2018;13:e0201314.
    >> Share

  110. NAGORSKI J, Allen GI
    Genomic region detection via Spatial Convex Clustering.
    PLoS One. 2018;13:e0203007.
    >> Share

    January 2017
  111. FAKKERT IE, van der Veer E, Abma EM, Lefrandt JD, et al
    Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    PLoS One. 2017;12:e0169673.
    >> Share

  112. SEEBACHER V, Reinthaller A, Koelbl H, Concin N, et al
    The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.
    PLoS One. 2017;12:e0169272.
    >> Share

  113. LEE HH, Bellat V, Law B
    Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.
    PLoS One. 2017;12:e0171044.
    >> Share

  114. BAI L, Wang H, Wang AH, Zhang LY, et al
    MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.
    PLoS One. 2017;12:e0173912.
    >> Share

  115. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
    PLoS One. 2017;12:e0174300.
    >> Share

  116. MA Z, Wang X, He J, Xia J, et al
    Increased expression of protein kinase CK2alpha correlates with poor patient prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0174037.
    >> Share

  117. COZZI GD, Levinson RT, Toole H, Snyder MR, et al
    Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0175119.
    >> Share

  118. BRENCICOVA E, Jagger AL, Evans HG, Georgouli M, et al
    Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
    PLoS One. 2017;12:e0175712.
    >> Share

  119. GRAUMANN R, Di Capua GA, Oyarzun JE, Vasquez MA, et al
    Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.
    PLoS One. 2017;12:e0177244.
    >> Share

  120. CHEN WC, Qiu JT, Lai CH, Huang HJ, et al
    Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    PLoS One. 2017;12:e0175703.
    >> Share

  121. LIU C, Zhang Y, Jiang H, Wu H, et al
    Association between social support and post-traumatic stress disorder symptoms among Chinese patients with ovarian cancer: A multiple mediation model.
    PLoS One. 2017;12:e0177055.
    >> Share

  122. Correction: Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0178965.
    >> Share

  123. STAFFORD JL, Dyson G, Levin NK, Chaudhry S, et al
    Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
    PLoS One. 2017;12:e0178450.
    >> Share

  124. ZHANG W, Su J, Xu H, Yu S, et al
    Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    PLoS One. 2017;12:e0179672.
    >> Share

  125. BJERSAND K, Seidal T, Sundstrom-Poromaa I, Akerud H, et al
    The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0179363.
    >> Share

  126. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2017;12:e0179501.
    >> Share

  127. WAN X, Bovornchutichai P, Cui Z, O'Neill E, et al
    Morphological analysis of human umbilical vein endothelial cells co-cultured with ovarian cancer cells in 3D: An oncogenic angiogenesis assay.
    PLoS One. 2017;12:e0180296.
    >> Share

  128. CHAO TK, Huang TS, Liao YP, Huang RL, et al
    Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    PLoS One. 2017;12:e0182166.
    >> Share

  129. LANDSKRON J, Kraggerud SM, Wik E, Dorum A, et al
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
    PLoS One. 2017;12:e0182030.
    >> Share

  130. PAULLIN T, Powell C, Menzie C, Hill R, et al
    Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses.
    PLoS One. 2017;12:e0182930.
    >> Share

  131. ROZENBLUM E, Sotelo-Silveira JR, Kim GY, Zhu JY, et al
    Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor.
    PLoS One. 2017;12:e0182610.
    >> Share

  132. PETERS IT, van Zwet EW, Smit VT, Liefers GJ, et al
    Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    PLoS One. 2017;12:e0168277.
    >> Share

  133. ZHU J, Wen H, Ju X, Bi R, et al
    Clinical Significance of Programmed Death Ligand1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
    PLoS One. 2017;12:e0170879.
    >> Share

  134. SEEBACHER V, Aust S, D'Andrea D, Grimm C, et al
    Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.
    PLoS One. 2017;12:e0182383.
    >> Share

  135. HAIMOVICH JS, Venkatesh AK, Shojaee A, Coppi A, et al
    Discovery of temporal and disease association patterns in condition-specific hospital utilization rates.
    PLoS One. 2017;12:e0172049.
    >> Share

  136. JIA ZH, Jia Y, Guo FJ, Chen J, et al
    Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
    PLoS One. 2017;12:e0183622.
    >> Share

  137. CHUNG YS, Kim YJ, Lee I, Lee JY, et al
    Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
    PLoS One. 2017;12:e0183754.
    >> Share

  138. ZHANG H, Lu J, Lu Y, Zhou J, et al
    Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma.
    PLoS One. 2017;12:e0177520.
    >> Share

  139. ROSSO M, Majem B, Devis L, Lapyckyj L, et al
    E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.
    PLoS One. 2017;12:e0184439.
    >> Share

  140. AYYAGARI VN, Diaz-Sylvester PL, Hsieh TJ, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    PLoS One. 2017;12:e0185111.
    >> Share

  141. GRANATA V, Fusco R, Catalano O, Avallone A, et al
    Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.
    PLoS One. 2017;12:e0179951.
    >> Share

  142. YANAGIDA S, Anglesio MS, Nazeran TM, Lum A, et al
    Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.
    PLoS One. 2017;12:e0178989.
    >> Share

  143. LIN KT, Sun SP, Wu JI, Wang LH, et al
    Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.
    PLoS One. 2017;12:e0178937.
    >> Share

  144. SUNG PL, Wen KC, Chen YJ, Chao TC, et al
    The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    PLoS One. 2017;12:e0185615.
    >> Share

  145. ZHU XM, Sun WF
    Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review.
    PLoS One. 2017;12:e0185456.
    >> Share

  146. TAO X, Chen L, Ge S, Cai L, et al
    Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis.
    PLoS One. 2017;12:e0177426.
    >> Share

  147. HARTER P, Hauke J, Heitz F, Reuss A, et al
    Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    PLoS One. 2017;12:e0186043.
    >> Share

  148. GUO Z, Wang X, Cheng D, Xia Z, et al
    Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.
    PLoS One. 2017;12:e0186965.
    >> Share

  149. VALIANATOS G, Valcikova B, Growkova K, Verlande A, et al
    A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.
    PLoS One. 2017;12:e0185801.
    >> Share

  150. FORNARO L, Vivaldi C, Lin D, Xue H, et al
    Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation.
    PLoS One. 2017;12:e0182818.
    >> Share

  151. YANG L, Zhang B, Xing G, Du J, et al
    Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2017;12:e0186725.
    >> Share

  152. GENG X, Liu Y, Diersch S, Kotzsch M, et al
    Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.
    PLoS One. 2017;12:e0186847.
    >> Share

  153. QIN L, Li T, Liu Y
    High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer.
    PLoS One. 2017;12:e0187385.
    >> Share

  154. CHESNAIS M, Lecuru F, Mimouni M, Ngo C, et al
    A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
    PLoS One. 2017;12:e0187245.
    >> Share

  155. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2017;12:e0187630.
    >> Share

  156. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeilinger R, et al
    Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2017;12:e0189641.
    >> Share

  157. KUROKI LM, Jin X, Dmitriev IP, Kashentseva EA, et al
    Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.
    PLoS One. 2017;12:e0190125.
    >> Share

  158. COUTTENIER A, Lacroix O, Vaes E, Cardwell CR, et al
    Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.
    PLoS One. 2017;12:e0189233.
    >> Share

  159. OBATA T, Nakamura M, Mizumoto Y, Iizuka T, et al
    Dual expression of immunoreactive estrogen receptor beta and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    PLoS One. 2017;12:e0188641.
    >> Share

  160. JIN D, Lee H
    FGMD: A novel approach for functional gene module detection in cancer.
    PLoS One. 2017;12:e0188900.
    >> Share

  161. CHEN Y, Bieber MM, Bhat NM, Teng NNH, et al
    Ovarian carcinoma glyco-antigen targeted by human IgM antibody.
    PLoS One. 2017;12:e0187222.
    >> Share

    January 2016
  162. TUMBARELLO DA, Andrews MR, Brenton JD
    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
    PLoS One. 2016;11:e0162698.
    >> Share

  163. XIAO X, Cai F, Niu X, Shi H, et al
    Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.
    PLoS One. 2016;11:e0163257.
    >> Share

  164. LI L, Luo Q, Xie Z, Li G, et al
    Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer.
    PLoS One. 2016;11:e0163447.
    >> Share

  165. IGNACIO RM, Kabir SM, Lee ES, Adunyah SE, et al
    NF-kappaB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
    PLoS One. 2016;11:e0164189.
    >> Share

  166. POCHECHUEVA T, Chinarev A, Schoetzau A, Fedier A, et al
    Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
    PLoS One. 2016;11:e0164230.
    >> Share

  167. FEDOSEIENKO A, Wieringa HW, Wisman GB, Duiker E, et al
    Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
    PLoS One. 2016;11:e0165385.
    >> Share

  168. SUN S, Cai J, Yang Q, Zhu Y, et al
    Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0166058.
    >> Share

  169. PENNINGTON M, Gentry-Maharaj A, Karpinskyj C, Miners A, et al
    Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    PLoS One. 2016;11:e0165539.
    >> Share

  170. RASOOL M, Malik A, Basit Ashraf MA, Parveen G, et al
    Evaluation of Matrix Metalloproteinases, Cytokines and Their Potential Role in the Development of Ovarian Cancer.
    PLoS One. 2016;11:e0167149.
    >> Share

  171. POWELL CD, Paullin TR, Aoisa C, Menzie CJ, et al
    The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.
    PLoS One. 2016;11:e0168389.
    >> Share

  172. TAO F, Ruan S, Liu W, Wang L, et al
    Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2016;11:e0168892.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016